Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854857 | 0.81 | KMT2A (0.47) | KMT2AHTTNPC1DYRK1AIDO1 | |
| SCHEMBL1104634 | 0.81 | KMT2A (0.56) | KMT2AHTTNPC1DYRK1AIDO1 | |
| SCHEMBL29607382 | 0.81 | HTT (0.56) | KMT2AHTTNPC1DYRK1AIDO1 | |
| SCHEMBL14051242 | 0.81 | HTT (0.56) | KMT2AHTTNPC1DYRK1AIDO1 | |
| SCHEMBL3146311 | 0.80 | KMT2A (0.50) | KMT2AHTTNPC1DYRK1AIDO1 | |
| SCHEMBL2067939 | 0.80 | KMT2A (0.46) | KMT2AHTTNPC1DYRK1AIDO1 | |
| SCHEMBL12681547 | 0.79 | HTT (0.42) | KMT2AHTTNPC1HSD17B10KDM4E | |
| SCHEMBL24567435 | 0.79 | KMT2A (0.54) | KMT2AHTTNPC1DYRK1AIDO1 | |
| Bromide SCHEMBL725234 | 0.79 | KMT2A (0.54) | KMT2AHTTNPC1DYRK1AIDO1 | |
| SCHEMBL14493846 | 0.79 | KMT2A (0.54) | KMT2AHTTNPC1DYRK1AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4587127-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics Incorporated (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20240407983-A1 | (R,E)-3,7-DIMETHYLNON-6-ENAL, ISOMERIC MIXTURES OF THE COMPOUND AND THE USE IN PERFUMERY | GIVAUDAN SA (CH) | 2024-12-12 | — | — | US | disclosed |
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-23 | — | — | US | disclosed |
| CN-118055916-A | (R, E) -3, 7-dimethyl-non-6-enal, isomer mixture of the compound and application in perfume | 奇华顿股份有限公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2024059806-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024059806-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| CN-102015686-A | Novel heterocyclic compounds and uses therof | NOVARTIS AG | 2011-04-13 | — | — | CN | disclosed |
| EP-2274300-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114942-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| CN-101573361-A | Novel aminopyrimidine derivative as plk1 inhibitor | BANYU PHARMA CO LTD (JP) | 2009-11-04 | — | — | CN | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| WO-2008081910-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | KMT2A 904/4885HTT 3644/4885NOS3 3049/4885 |
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | ABCG2, BRIX1, MRPS28 | KMT2A 4133/4885HTT 3121/4885NOS3 4809/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KMT2A 2069/4885HTT 2514/4885NOS3 4868/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | KMT2A 2069/4885HTT 2514/4885NOS3 4868/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KMT2A 2069/4885HTT 2514/4885NOS3 4868/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | KMT2A 2016/4885HTT 2408/4885NOS3 4589/4885 |
| US-20240407983-A1 | (R,E)-3,7-DIMETHYLNON-6-ENAL, ISOMERIC MIXTURES OF THE COMPOUND AND THE USE IN PERFUMERY | CYP2D6, G6PD, ECI1 | KMT2A 4604/4885HTT 4606/4885NOS3 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.